Fig. 4: VIS cells are sensitive to senolytic targeting.

a, Immunoblots of BCL-2 family members (left) and kinases (right) in HDF lysates as indicated (α-tubulin was used as a loading control). b, The relative viability of IMR90 cells, as in Fig. 1e, 48 h after treatment with senolytics as indicated or with solvent-only (dimethyl sulfoxide (DMSO)). c, Viability of HNEpC-hACE2 cells infected with SARS-CoV-2 or mock, and treated with senolytics as indicated for c–f. d, The relative change of the CD86⁺ fraction in the THP-1 cell population after receiving supernatant from HNEpC-hACE2 cells as in c. Of note, supernatant transfer experiments were carried out in the presence of SARS-CoV-2-neutralizing anti-spike antibodies, which prevented the transmission of infection (as evidenced by negative target cell SARS-CoV-2 PCR, data not shown). e, Quantification of SA-β-gal staining of HUVEC endothelial cells after receiving supernatant from HNEpC-hACE2 cells as in d. f, Quantification of C5b–C9 on HUVEC cells exposed to human serum with supernatant from HNEpC-hACE2 cells as in d. All bar plots in this figure show the mean ± s.d. of n = 3 independent experiments with individual values as dots. *P < 0.05 by unpaired two-tailed t-test.